tiprankstipranks
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market
Holding SMMT?
Track your performance easily

Summit Therapeutics (SMMT) Ownership - Who Owns Summit Therapeutics?

993 Followers

Summit Therapeutics (SMMT) Ownership Overview

80.14%2.60%0.12%2.53%14.61%
80.14% Insiders
0.12% Other Institutional Investors
2.53% ETFs
14.61% Public Companies and Individual Investors
The ownership structure of Summit Therapeutics (SMMT) stock is a mix of institutional, retail, and individual investors. Approximately 5.25% of the company’s stock is owned by Institutional Investors, 80.14% is owned by Insiders, and 14.61% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 03, 2024
Maky Zanganeh
Co Ceo,director
xxxxxxxxxxxxx
$498776
Mar 27, 2024
Maky Zanganeh
Co Ceo,director
xxxxxxxxxxxxx
$411094
Mar 27, 2024
xxxxxxxxxxxxx
$375000
Dec 13, 2023
Maky Zanganeh
Co Ceo,director
xxxxxxxxxxxxx
$1204108

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$152100
Jun 30, 2024
xxxxxxxxxxxxx
$941818
Jun 30, 2024
xxxxxxxxxxxxx
$181133331

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
551,695,096Insider74.81%12,010,402,240
35,738,442Insider4.85%778,025,882
23,222,222Institution3.15%505,547,773
10,627,632Institution1.44%231,363,549
7,752,569Institution1.05%168,773,427
4,813,099Institution0.65%104,781,165
4,784,429Institution0.65%104,157,019
3,020,242Insider0.41%65,750,668
1,664,374Institution0.23%36,233,422
1,338,361Institution0.18%29,136,119

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,752,569Institution1.05%168,773,427
4,784,429Institution0.65%104,157,019
1,664,374Institution0.23%36,233,422
992,476Institution0.13%21,606,203
850,583Institution0.12%18,517,192
750,000Institution0.10%16,327,500
537,522Institution0.07%11,701,854
525,834Institution0.07%11,447,406
442,474Institution0.06%9,632,659
272,395Institution0.04%5,930,039

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,427,980Institution0.46%75,072,762
2,717,802Institution0.37%59,519,864
2,399,427Institution0.33%52,235,526
2,061,555Institution0.28%45,148,055
1,842,797Institution0.25%40,357,254
1,217,344Institution0.17%26,063,335
744,383Institution0.10%16,205,218
665,561Institution0.09%14,249,661
605,183Institution0.08%13,174,834
401,498Institution0.05%8,792,806

FAQ

Who Owns Summit Therapeutics (SMMT)?
According to the latest TipRanks data, approximately 0.12% of the company's stock is held by institutional investors, 80.14% is held by insiders, and 14.61% is held by retail investors.
    What percentage of Summit Therapeutics (SMMT) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 0.12% of Summit Therapeutics (SMMT) stock is held by institutional investors.
      What percentage of Summit Therapeutics (SMMT) stock is held by retail investors?
      According to the latest TipRanks data, approximately 14.61% of Summit Therapeutics (SMMT) stock is held by retail investors.
        Who owns the most shares of Summit Therapeutics (SMMT)?
        Robert Duggan owns the most shares of Summit Therapeutics (SMMT).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis